Warming is expanding tick habitat globally. Switzerland: tick-suitable area grew from ~16% (2009) to >25% by 2024. TBE cases rose from 112 (2014) to 436 (2024) — 4× in a decade. Australia: east coast tick range expanding southward and into higher altitudes. Climate-tick nexus is a funded 2026 research priority internationally.
Shared TRPM3 Endpoint
Post-infectious ME/CFS follows multiple global triggers: Borrelia (Lyme), Coxiella (Q Fever), SARS-CoV-2 (Long COVID), EBV, enterovirus. Griffith University 2026 confirmed TRPM3 NK cell dysfunction as the shared cellular endpoint across these diverse triggers — a unifying mechanism with global translational significance beyond Australia.
IACFS/ME 2025 Conference Key Themes
The IACFS/ME 2025 conference confirmed: neuroinflammation and autonomic nervous system abnormalities precede other ME/CFS pathology. LDN restored TRPM3 in 9 Long COVID patients — TRPM3 currents matched healthy controls post-treatment. Multi-system vicious cycle identified: immune → autonomic → circulatory → endocrine → energy metabolism. Source: Medscape, Nov 2025.
Lyme Confirmed (UK)
3,000+/yr
↑ Lab-confirmed · UKHSA · significant under-count
Borrelia in Ticks (UK)
8–15%
Ixodes ricinus · England & Wales · 2021–2023
ME/CFS Prevalence
250k+
↑ Estimated UK patients
NICE Guideline Shift
2021
↓ GET removed · pacing mandated
UK Research Institutions — Relevant to NanaLens
UKHSA Medical Entomology & Zoonoses: National tick surveillance — model for AU system
LSHTM: Global Lyme epidemiology meta-analyses · tick ecology modeling
Oxford Univ. / DecodeME: World's largest ME/CFS genetic study (2022) — 17,000+ participants
Published July 2025 in Ticks & Tick-Borne Diseases (doi: 10.1016/j.ttbdis.2025.102523): Borrelia prevalence in questing I. ricinus at recreational areas across England & Wales, 2021–2023. This study provides the surveillance methodology template that Australia's 2025 Senate Inquiry recommended implementing nationally. Direct comparison: UK has validated surveillance; Australia has none.
Lyme Diagnoses (CDC est.)
476k/yr
↑ ~10× official surveillance reports
ME/CFS Prevalence
3.3M+
↑ CDC estimate · significantly underfunded
Lyme Doubled
2×
↑ 2010–2021 · BMJ Global Health meta-analysis
CDMRP TBD Fund
FY26
↑ Congressional funding · high-impact research mandate
US Research — Direct Relevance to NanaLens
NIH RECOVER Initiative: Largest post-COVID/ME/CFS research program globally — TRPM3 intersection
Open Medicine Foundation: ME/CFS precision medicine — metabolomics + proteomics data relevant to AU research design
CDMRP FY2026: Tick-Borne Disease Research Program — potential collaboration funding for AU researchers
US vs AU Diagnostic Comparison
Factor
USA
Australia
B. burgdorferi
Endemic confirmed
Not confirmed endemic
Serology
Two-tier ELISA/WB
No validated local test
Test access
Standard clinical
Overseas labs (patient cost)
TRPM3 test
Research only
NCNED provisional patent
Vaccine
VLA15 Phase 3
Q-VAX only
TBE Cases EU/EEA 2022
3,500+
↑ 14% increase · ECDC Annual Report
TBE Notification Rate
0.81/100k
EU/EEA 2022 · male:female 1.5:1
Swiss TBE Cases
436
↑ 2024 vs 112 in 2014 · 4× in a decade
Tick Habitat Expanded
>25%
↑ Switzerland territory suitable · was 16% (2009)
ECDC Surveillance Model — What AU Lacks
Europe: standardised TBD surveillance across 20+ countries; annual ECDC epidemiological reports; national vaccination programs (TBE vaccine widely used in Austria, Germany, Czech Republic); validated two-tier Lyme serology; TBE notifiable in all EU/EEA countries.
Australia (2026): NO standardised surveillance; NO validated domestic serology; DSCATT NOT notifiable; 2025 Senate Inquiry recommended building this infrastructure urgently. NanaLens is a data infrastructure prototype for this purpose.
European vs Australian TBD — Key Differences
EU dual burden: Lyme (bacterial) AND TBE (viral) — Australia has NO TBE
EU vector: Ixodes ricinus (does NOT carry TBE in AU context)
AU vector: Ixodes holocyclus — unique evolutionary lineage — 130M yr isolation since Gondwana
EU vaccine: TBE vaccine widely used; Lyme VLA15 in Phase 3
AU vaccine: Q-VAX only; no Lyme/DSCATT vaccine in development
Pathogens, Vectors & DSCATT
Australian confirmed endemic species · Lyme-like illness · Diagnostic landscape · 17 human-biting tick species
Primary Vector — Ixodes holocyclus
Ixodes holocyclus — The Australian Paralysis Tick
Responsible for >95% of tick bites in Australia. Found along the east coast in coastal and hinterland scrub from North Queensland to eastern Victoria. Unique evolutionary lineage — 130–135 million years of Gondwanan isolation has produced a tick fauna phylogenetically distinct from Northern Hemisphere species. This isolation may explain why classical diagnostic serology fails: AU tick pathogens are related to, yet distinct from, known northern hemisphere tick-borne pathogens.
>95% of bitesEast Coast130M yr evolutionary isolation
Source: Frontiers Cell. Infect. Microbiol. 2019 · PMC6360175 · "Human Tick-Borne Diseases in Australia" · Charles Perkins Centre / Univ. Sydney
DSCATT — Clinical Definition & Status
Debilitating Symptom Complexes Attributed to Ticks
Australia's official clinical term since 2018, replacing contested "Lyme-like illness" and "Chronic Lyme Disease." Used for patients with persistent debilitating symptoms following tick exposure where a definitive pathogen-based diagnosis cannot be established. The 2025 Senate Inquiry recommended renaming to reduce stigma. The true scale is difficult to estimate because: (1) no appropriate case definition exists; (2) tick-borne infections are not notifiable (except Q Fever); (3) data on tick bites and sequelae are not systematically collected.
Stigma under reviewDiagnosis of exclusion2025 Senate Inquiry
Source: PMC9694322 · "Troublesome Ticks Research Protocol" · Frontiers Microbiology
All Known/Suspected Human-Pathogenic Tick-Borne Agents · Australia
Patient presents with fatigue, PEM, joint pain, cognitive symptoms following tick bite
TESTING
No validated Australian test exists. Standard serology: often negative or cross-reactive. Patients fund overseas labs personally (USA, Germany).
DIAGNOSIS
DSCATT applied by exclusion. Frequent patient disbelief. Average diagnostic delay: years. Stigma documented by Senate Inquiry 2025.
2026 OPPORTUNITY
TRPM3 biomarker (Griffith 2026) + saliva-based ion channel diagnostic (NCNED provisional patent AU 2022902253) may provide Australia's first objective ME/CFS diagnostic pathway.
Q Fever → ME/CFS: Australia's Strongest Documented Link
Coxiella burnetii is the most robustly documented Australian post-infectious ME/CFS trigger. The Dubbo studies (Marmion 2000–2009) followed cohorts for 10+ years, confirming 10–15% develop Q Fever Fatigue Syndrome meeting full ME/CFS diagnostic criteria.
~700 notifiable cases/year — significant under-count; aerosol transmission from livestock
Q-VAX: Only AU tick-borne disease vaccine — recommended for occupational risk groups (abattoir, livestock, veterinary workers)
Post-Q fever: Identical TRPM3 NK cell dysfunction profile to ME/CFS (Griffith NCNED 2024)
Chronic Q fever: Endocarditis in immunocompromised — distinct from Q Fever Fatigue Syndrome
TRPM3 Ion Channel Mechanism
Griffith University NCNED · Jan 2026 · Frontiers in Medicine · doi:10.3389/fmed.2025.1703924
The Stuck Door — Cellular Basis of ME/CFS & Post-Tick Immune Failure
Prof. Sonya Marshall-Gradisnik · Dr Etianne Sasso · NCNED Griffith (QLD) + UWA (WA) · January 2026
Study Participants
78
36 ME/CFS · 42 healthy controls
Independent Labs
2
Gold Coast (QLD) + UWA Perth (WA) · 4,000+ km
Result
p<0.05
Significant · location-independent · reproducible
Method — Whole-Cell Patch-Clamp Electrophysiology
Glass micropipette seals to a single NK cell membrane — measures ionic current at picoampere (10⁻¹² A) precision. TRPM3 currents stimulated with pregnenolone sulphate (PregS). Freshly isolated NK cells from both cohorts assessed. Result was identical across labs — this is biology, not methodology artifact.
NCNED Research Timeline — TRPM3 Discovery Pathway
2017
Reduced NK cell cytotoxic activity confirmed in ME/CFS
2019
TRPM3 genetic variants identified in ME/CFS patients
2021
TRPM3 protein expression changes confirmed in NK cells
Gap: No Phase II/III RCT in Australian DSCATT/ME/CFS cohorts yet. TRPM3 as pharmacodynamic biomarker for trial design is a critical 2026 research opportunity.
7T MRI Neuroimaging Findings (Griffith 2025)
Hippocampal volume: Significantly larger in ME/CFS AND Long COVID vs healthy controls (PLOS ONE 2025). Similar hippocampal volume between ME/CFS and Long COVID — striking brain similarities confirming shared pathology.
Neurochemicals (Am. J. Medicine 2024): Significantly elevated neurochemical levels in both conditions vs controls. Levels correlated with cognitive impairment, unrefreshing sleep, pain, and physical limitation. Suggests neuroinflammatory basis for cognitive dysfunction.
$438k NHMRC grant for longitudinal 7T MRI study of ME/CFS progression over 3 years — Assoc. Prof. Leighton Barnden CIA
iPSC Drug Screening Program (Active 2025)
NHMRC-funded program using induced pluripotent stem cells (iPSC) from ME/CFS patients to generate:
• Cortical networks (10/16 complete 2024) • Skeletal muscle cells for mitochondrial function study
Drug repurposing screen using gene expression signature — targeting off-patent drugs with known safety profiles for rapid progression to clinical trials.
PEM is a pathological worsening of ALL symptoms following minimal physical or cognitive exertion — typically with a 24–72 hour delay. It is NOT ordinary fatigue, NOT deconditioning. It clinically distinguishes ME/CFS from all other fatigue conditions. Directly linked to TRPM3-impaired Ca²⁺ signalling: muscles, neurons, and immune cells cannot recover because calcium-dependent energy and repair mechanisms are compromised at the cellular level. Graded Exercise Therapy (GET) is CONTRAINDICATED — formally removed from NICE guidelines 2021.
100% of diagnoses24–72hr delayCanadian Consensus Criteria requirementNICE 2021: GET contraindicated
Symptom Frequency · Australian DSCATT/ME/CFS Cohorts
Profound fatigue97%
Post-exertional malaise95%
Cognitive dysfunction88%
Sleep disturbance (unrefreshing)85%
Cardiovascular/POTS (QLD)81%
Musculoskeletal pain79%
Orthostatic intolerance78%
Temperature dysregulation72%
GI dysfunction65%
Source: Sasso et al. 2026 · NCNED Griffith + UWA multi-site
"Brain Fog" → Neurocognitive Dysfunction Reframe
"Brain fog" obscures the clinically documented mechanism: neuroinflammation with measurable neurochemical imbalance. Griffith 7T MRI studies show enlarged hippocampal volume and elevated neurochemicals in ME/CFS, correlating with cognitive symptoms.
Research Reference — 36 Knowledge Cards
Post-doctoral career resource · Research knowledge base · ME/CFS · TBD · Translational medicine · Grows with your career
Career Tools — Post-Doctoral Edition
NSW Health · University of Sydney · Research career infrastructure
Journal Selection Guide
Q1 targets for TRPM3/ME/CFS work:
· Frontiers in Medicine (your field's home journal, IF 3.1)
· Journal of Translational Medicine (IF 6.1)
· Brain, Behavior & Immunity (neuroimmune, IF 8.8)
· PLOS ONE (open-access, fast turnaround)
· Emerging Infectious Diseases (CDC; tick-borne focus)
· Medical Journal of Australia (AU policy impact)
Key Conferences 2026–2027
· IACFS/ME 2026 — International ME/CFS conference (abstract due ~Jun 2026)
· AACR / NHMRC Symposia — Biomarker sessions; AU funding alignment
· Australasian Virology Society — post-infectious disease intersection
· Public Health Association AU — DSCATT surveillance policy
· ANZSCDB — Cell biology; ion channel sessions
Grant Calendar 2026
· NHMRC Ideas Grant — Opens ~Mar; closes ~Jun. Budget up to $400k/2yr
· MRFF Emerging Leader — Competitive; requires CCI plan. Watch funding.gov.au
· CDMRP Tick-Borne FY26 — US/AU collaborative; IRB + HREC dual approval
· NSW Health Research Support — Internal; talk to your Research Office on day one
· Perpetual IMPACT — Philanthropic; ME/CFS patient community aligned
Estimate DSCATT/ME/CFS burden in any Australian region based on known incidence parameters. Adjust variables to model different scenarios for your research proposal.
↑ Enter parameters and click Model to generate estimate.
Research Cohort Size Calculator
Estimate required sample size for a TRPM3 biomarker study based on Griffith University\'s validated methodology (effect size from Sasso et al. 2026).
↑ Parameters based on Sasso et al. 2026 (n=78, p<0.05) as validated reference.
Australian Tick Season & ME/CFS Temporal Correlation Explorer
Visualise the temporal relationship between peak tick season (Jul–Nov) and DSCATT presentation lag (~2–8 weeks post-bite). This is foundational data for a prospective surveillance study.
Estimated correlation for research hypothesis generation. Prospective surveillance data needed to validate. This is a core research gap identified by the 2025 Senate Inquiry.
TRPM3 Current vs Symptom Severity (Sasso et al. 2026)
Illustrative correlation from Sasso et al. 2026 multi-site data · doi:10.3389/fmed.2025.1703924
ME/CFS Economic Burden Model (Australia)
Estimated · NCNED health economics analysis · Centre for Applied Health Economics collaboration
Proposed NanaLens Study Design — NSW East Coast
T0 (Enrolment)
DSCATT-suspected patients · NSW east coast clinics · baseline TRPM3 NK cell test
Full symptom trajectory vs TRPM3 status · LDN treatment arm (Phase II)
Publication
First AU translational ME/TBD longitudinal dataset · JAMA/Lancet target
R Code Generator
Generate ready-to-run R scripts for your research analysis
Select Analysis Type
TRPM3 Biomarker Analysis
✓ Copied to clipboard — paste into RStudio or R console
Python Code Generator
pandas · scikit-learn · geopandas · matplotlib — NSW Health data science stack
Select Python Script
APDC Data Wrangling
✓ Copied to clipboard — paste into Jupyter, VS Code, or terminal
Statistical Modelling Toolkit
Brainstorming Boosters — Live Research Console
Clinical case simulator · Risk score tool · Treatment curves · Timeline model · Export to Jupyter & Streamlit
Generate Patient Profile
Click "Generate" to synthesise a realistic DSCATT/ME/CFS patient profile based on Sasso et al. 2026 cohort parameters and the Troublesome Ticks Protocol (PMC9694322).
Symptom Radar — Generated Case
Based on NCNED/Griffith cohort frequency data · Sasso 2026
TRPM3 Probability Estimator — Clinical Input
Research tool only — not a diagnostic instrument. Intended for cohort design and hypothesis generation.
Risk Score Output
—
Enter values and calculate
LDN/NTX Treatment Response Simulator — TRPM3 Recovery Model
Simulated curves based on in vitro LDN data (IACFS/ME 2025) and Q Fever Fatigue Syndrome longitudinal studies. Phase II RCT not yet conducted in AU DSCATT. These curves represent hypothesis-generation scenarios for research design.
DSCATT → ME/CFS Progression Timeline — Interactive Model
🩺
DSCATT Clinical Decision Console
Research-grade · Not for clinical use · Sasso 2026 methodology
TRPM3 Status
—
Generate a case first
PEM Severity
—
—
Diagnostic Fit
—
—
Recommended Research Actions
Generate a case to see research pathway recommendations.
Relevant Biomarkers
—
Smart Library
Peer-reviewed · Australian-focused 2018–2026 · Senate Inquiry · Global context · Filter by category
Clinical Note · Pacing Protocol & GET Contraindication
Pacing is the only evidence-based activity management for ME/CFS. Graded Exercise Therapy (GET) is contraindicated — formally removed from NICE guidelines (2021) based on evidence it worsens PEM and long-term function. This tracker supports heart-rate-based pacing: patients stay below anaerobic threshold (~50–60% max HR) to prevent PEM triggering. Data from this tracker is structured for direct import into clinical research databases.
My Notes — Edit Engine
Add personal notes · Tables · Statistics · Links · Citations · Diagrams · Stored in session
Click a tool above to start adding research notes. All notes are preserved during this session and can be exported.
Translational Medicine Bridge
From bench to bedside · NanaLens as infrastructure · Research design · University of Sydney alignment
NanaLens as a Living Microscope — First Principles Architecture
Translational medicine bridges laboratory discovery to clinical benefit. In Australian ME/CFS and DSCATT research, this gap has been profound. The 2026 TRPM3 discovery is a watershed — but it is meaningless without infrastructure to translate it. NanaLens doesn't just store data; it allows the researcher to see patterns through a lens of first principles — connecting the cellular mechanism (TRPM3) to geographic prevalence (East Coast hotspots) to patient symptom trajectories (PEM logging), in real time, across global contexts. The platform is designed for your ongoing research, not just a single interview.
Lab → Clinic Pipeline
1
Biomarker Discovery (Griffith 2026)
TRPM3 dysfunction confirmed in NK cells as consistent, reproducible, location-independent biomarker across two independent Australian labs. Frontiers in Medicine doi:10.3389/fmed.2025.1703924
2
Diagnostic Test Scaling
NK cell isolation → TRPM3 current measurement → threshold-based positive/negative output. NCNED provisional patent AU 2022902253 covers saliva-based ion channel platform — lower barrier than blood draw.
3
Clinical Guideline Integration
TRPM3 criteria embedded in GRADE-based DSCATT clinical pathway (2025 Senate Inquiry mandate). Replaces diagnosis-of-exclusion with objective biological confirmation — ending years of patient disbelief.
4
Therapeutic Trials (NTX/LDN)
Phase II/III RCTs using TRPM3 activity as inclusion criterion AND pharmacodynamic biomarker — enabling precision medicine for Australian DSCATT patients. LDN in vitro data from IACFS/ME 2025.
5
NanaLens Patient Data Feedback Loop
Real-world symptom data (PEM frequency, geographic clustering, biomarker status) feeds back into research longitudinally — linking lived experience to cellular mechanism. Australia's first integrated ME/TBD registry.
University of Sydney Research Alignment
The University of Sydney hosts the Charles Perkins Centre (Sydney Medical School) and the Marie Bashir Institute for Infectious Diseases and Biosecurity — both directly relevant. Faculty at UoS contributed to the 2019 Frontiers paper on "Human Tick-Borne Diseases in Australia" (PMC6360175) establishing AU tick taxonomy and pathogen landscape.
The Macquarie University Neuroinflammation Group (collaborating with UoS) provides neuroimmunology infrastructure relevant to the TRPM3/neuroinflammation research direction.
Likely interview question: "How would you validate this platform in a prospective clinical study?"
Model answer: Recruit DSCATT-suspected patients across NSW east coast clinics → baseline TRPM3 NK cell assessment → 12-month NanaLens symptom tracking → correlate symptom trajectory with biomarker status → publish as Australia's first translational ME/TBD longitudinal dataset. Ethics pathway: Sydney Local Health District HREC.
Critical Research Gaps — 2026 Agenda
Epidemiological: No validated national DSCATT prevalence figure exists. NanaLens tracker is prototype registry infrastructure.
Pathogen: Novel Borrelia species in AU ticks unresolved. Metagenomic tick surveys + human seroprevalence urgently needed.
Therapeutic: LDN/NTX RCTs not yet conducted in AU DSCATT/ME/CFS populations. TRPM3 as pharmacodynamic biomarker = ideal Phase II design.
Surveillance: Tick season → DSCATT presentation temporal correlation unstudied prospectively. NanaLens data mining module designed for this.
Research Governance
Ethics · Biosafety · HREC · Informed Consent · Data Governance · Australian regulatory framework
NHMRC National Statement on Ethical Conduct in Human Research (2023)
The primary Australian framework governing all human research — mandatory for HREC submission
Chapters directly applicable to DSCATT research
Chapter 2.1 — Respect for Persons: Autonomy and consent. Critical for DSCATT: patients are often desperate for diagnosis — their vulnerability must be explicitly acknowledged in the ethics application. The National Statement requires demonstration that recruitment does not exploit this desperation.
Chapter 3.1 — Ethical review: All research involving humans requires HREC review. Tick-bite cohort studies, NK cell isolation, skin biopsies, and symptom tracking all require full review (not expedited) given the physical procedures involved.
Chapter 2.2 — Research merit and integrity: The research question must be significant, the methodology sound, and the researchers must have appropriate expertise. For TRPM3 patch-clamp work, this means demonstrating access to validated electrophysiology infrastructure.
Chapter 3.3 — Participant selection: DSCATT patients cannot be selected solely because they are available or easy to recruit. Selection must be scientifically justified and equitable.
Key ethical tensions specific to DSCATT research
Therapeutic misconception: Participants may believe TRPM3 testing is diagnostic rather than experimental. Consent documentation must distinguish research from clinical care with explicit language.
Diagnostic limbo and distress: Many DSCATT patients have waited years for answers. Being enrolled in a study that may not yield a diagnosis creates psychological risk. A mental health support pathway must be documented in the protocol.
Community trust: The ME/CFS and DSCATT community has experienced sustained institutional disbelief. The ethics application must include a genuine patient advisory process — not tokenistic consultation — and demonstrate how patient priorities shaped the research design.
Overseas testing: Some participants fund overseas laboratory tests. Research findings must not be communicated in ways that suggest validation or clinical utility beyond their research scope.
OGTR Biosafety Classification — Australian Tick-Borne Research
Office of the Gene Technology Regulator · Physical Containment levels for DSCATT laboratory work
PC1 — Physical Containment Level 1
Applies to:
· NK cell isolation from peripheral blood (healthy volunteers and ME/CFS patients)
· TRPM3 whole-cell patch-clamp electrophysiology on isolated NK cells
· Standard blood processing (PBMC isolation by Ficoll gradient)
· Cell culture of established lines (ISE6, XTC-2, Ju56, Vero — per Troublesome Ticks Protocol)
· iPSC-derived cortical networks and skeletal muscle cells
Key requirements: Lab coat and gloves mandatory. No mouth pipetting. Biohazard disposal in sealed yellow bins. Standard laboratory disinfectants (70% ethanol, 1% hypochlorite). Sharps protocol for needles used in blood collection.
PC2 — Physical Containment Level 2
Applies to:
· Coxiella burnetii (Q Fever agent) — Biosafety Group 3 pathogen in Australia
· Rickettsia australis (Queensland Tick Typhus) — Biosafety Group 3
· Rickettsia honei (Flinders Island Spotted Fever) — Biosafety Group 3
· Live tick handling and dissection (Ixodes holocyclus) for pathogen extraction
· Skin biopsy samples from tick-bite sites with unknown pathogen status
Key requirements: PC2 certified facility with restricted access. Biological safety cabinet (Class II) mandatory for all aerosol-generating procedures. Autoclaving of all waste before disposal. Institutional Biosafety Committee (IBC) approval required before commencement. Annual biosafety training certification.
Important: Rickettsia spp. and C. burnetii
Both are notifiable diseases in Australia. Any confirmed culture or isolation must be reported to the relevant State Health authority. C. burnetii is a potential bioterrorism agent — additional DAFF notification may be required under the Security Sensitive Biological Agent (SSBA) framework.
HREC Application — Sydney Local Health District
The specific ethics body for University of Sydney-affiliated clinical research at Royal North Shore and associated sites
Sydney LHD HREC uses the Research Ethics and Governance Information System (REGIS) — the NSW Government's centralised online submission platform. All applications are submitted through regis.health.nsw.gov.au. Allow 8–12 weeks for full HREC review.
Protocol Documents Required
✓ Research protocol (structured per NHMRC format)
✓ Investigator brochure / scientific background
✓ Participant Information Sheet (PIS)
✓ Informed Consent Form (ICF)
✓ Recruitment materials (ads, scripts)
✓ Data collection instruments (NanaLens tracker)
✓ Statistical analysis plan
✓ CVs for all investigators
✓ Site/facility certifications (PC2 if applicable)
DSCATT-Specific Protocol Elements
✓ Justification for invasive procedures (skin biopsy, venepuncture)
✓ PEM management plan for participants who crash post-visit
✓ Psychological support pathway for patients receiving no diagnosis
✓ Patient Advisory Board composition and role
✓ Data return policy (will you share results with participants?)
✓ Overseas laboratory use justification
✓ TRPM3 testing: research-only disclaimer
✓ Biobank consent (separate from study consent)
Common HREC Review Issues
⚠ Therapeutic misconception language in PIS
⚠ Undefined pathway for incidental findings
⚠ Insufficient data security plan for sensitive health data
⚠ Recruitment through patient advocacy groups — conflicts of interest
⚠ Biobank without separate tiered consent
⚠ No plan for communicating null results to participants
⚠ Post-study access to TRPM3 testing not addressed
⚠ Payment to participants — must not be coercive
Informed Consent — DSCATT Cohort
Plain-language PIS requirements (NHMRC standard)
The Participant Information Sheet must be written at no higher than a Year 8 reading level (Flesch-Kincaid). It must include: what the study involves; what is experimental versus standard care; how much time participation requires; all risks including PEM risk from study visits; benefits — and crucially, the statement that participation may provide no personal health benefit; how data will be stored and for how long; the right to withdraw without consequence; and contact details for the independent complaints person.
Critical language for DSCATT consent
"The TRPM3 test we will perform on your blood cells is a research test only. It is NOT a diagnostic test and its results will NOT be shared with your doctor or added to your medical record. Participation in this study will not tell you whether you have ME/CFS, DSCATT, or any other condition."
Data Governance — Australian Requirements
Privacy Act 1988 (Cth) — Australian Privacy Principles (APPs):
APP 3: Collection of health information requires consent. APP 6: Health information may only be used for the primary purpose of collection. APP 11: Active measures to protect health information from misuse, interference, and loss.
NSW Health Records and Information Privacy Act 2002:
Applies to all NSW public health organisations including Sydney LHD. Health Privacy Principles (HPPs) govern collection, use, disclosure, and retention of health information. Research exemption applies only with HREC approval.
De-identification standard:
NHMRC requires data to be de-identified using the AIHW De-identification Manual standard. For small DSCATT cohorts (n<100), quasi-identifiers (postcode, age, rare diagnoses) may re-identify participants even after name removal — seek statistical de-identification advice.
Retention:
Human research data must be retained for a minimum of 15 years after publication (NHMRC). Biological samples: indefinitely or as per biobank consent. Secure destruction after retention period.
What Funding Bodies Require — NHMRC, MRFF, CDMRP
NHMRC (Australia)
HREC approval before any funding can be drawn down. Ethics letter must be attached to all progress reports. Any protocol amendments require HREC re-approval and NHMRC notification. Animal research (if any): AEC approval. Gene technology: OGTR licence if applicable. Clinical trials: ANZCTR registration mandatory.
MRFF (Australia)
Medical Research Future Fund grants require Consumer and Community Involvement (CCI) plan — not optional. Patient advisory boards must be documented with meeting minutes. Translation pathway must be explicit: how does this research reach patients within 10 years?
CDMRP (USA — collaborative)
Congressional Defense Medical Research Program FY2026 Tick-Borne Disease Research Program requires IRB approval (US equivalent of HREC). For international collaborations: both Australian HREC and US IRB required. Data sharing agreement required for any samples or data crossing borders. ITAR/export control review for certain biological materials.
NSW Health Data Infrastructure — Day-One Reference
PHISN · APDC · MBS/PBS Linkage · SAPHaRI — the datasets you will be asked to work with
PHISN — Public Health Information & Surveillance Network
NSW Health's central communicable disease surveillance system. Captures notifiable disease notifications, outbreak investigations, and syndromic surveillance data in real-time.
Relevance for DSCATT research: Q Fever (Coxiella burnetii) is notifiable in NSW — PHISN holds all confirmed case records. While DSCATT itself is not notifiable, PHISN data enables geographic correlation between Q Fever incidence and DSCATT/ME/CFS presentations.
Access: Through your NSW Health supervisor or the Health Protection NSW Epidemiology Unit. Requires data custodian approval and ethics clearance. Portal: phisn.health.nsw.gov.au
APDC — Admitted Patient Data Collection
Mandatory collection of all inpatient separations from NSW public and private hospitals. Contains: ICD-10-AM diagnosis codes, procedures, LOS, admission/discharge dates, postcode.
Relevance: Identifying ME/CFS (ICD-10: G93.3) and tick-related presentations (W57: "Contact with non-venomous insects and other non-venomous arthropods") in the hospital system. APDC enables burden-of-disease analysis and geographic mapping of DSCATT-adjacent diagnoses across NSW.
Access: Centre for Health Record Linkage (CHeReL) — apply via cherel.com.au. HREC approval required. Turnaround 3–6 months for linked data.
MBS/PBS Linkage — Medicare & Pharmaceuticals
Held by AIHW (Australian Institute of Health and Welfare). Medicare Benefits Schedule (MBS) captures every GP and specialist consultation billed to Medicare. Pharmaceutical Benefits Scheme (PBS) records all subsidised prescriptions dispensed.
Relevance: Tracking the diagnostic journey of DSCATT patients — how many specialist referrals before DSCATT recognition? Which medications (LDN is NOT PBS-listed — patients pay out of pocket) are prescribed? MBS/PBS linkage to APDC creates a longitudinal picture of the healthcare utilisation burden.
Access: AIHW Data Integration Services — aihw.gov.au/about-our-data. Requires ethics + AIHW data governance approval. Budget 6–12 months from application.
SAPHaRI & CHeReL — Linkage Platform
SAPHaRI (Secure Analytics for Population Health Research & Intelligence) is NSW Health's secure data analytics environment — a virtual workspace where approved researchers analyse linked data without data leaving the secure environment.
CHeReL (Centre for Health Record Linkage) is the NSW/ACT linkage authority. Probabilistic matching links records across APDC, ED data, mental health, cancer registries, and MBS/PBS using name, DOB, and address — without sharing identifiers with researchers.
Practical tip: On day one, ask your supervisor about SAPHaRI access. Many NSW Health post-docs work inside SAPHaRI rather than receiving raw data files. The Python code generator in NanaLens is optimised for SAPHaRI's pandas/Python environment.
Key contacts to establish on Day 1
· Your Research Office (contracts, ethics, access requests)
· NSW Ministry of Health Data Analytics Centre (DAC)
· CHeReL liaison for linkage projects
· Your institution's research data librarian (SAPHaRI onboarding)
Add Note
✨ AI Fill — describe what you want, AI writes all fields